Stockreport

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF - Marketing Authorization Application for treatment of cholestatic disease in Alagille syndrome submitted.- Natural history analysis shows significant improvement in eve [Read more]